Background/Aims: Osteogenesis imperfecta (OI) is a hereditary disease causing increased bone fragility. Pamidronate (PAM), which has to be administered as a 3-day course according to the original protocol by Glorieux, is the most frequently used therapy. Other bisphosphonates like neridronate (NER), which can be infused during an outpatient visit, have also proven to be effective. This is the first analysis comparing the effect of PAM and NER using vertebral morphometry. Methods: 28 patients with OI type III and IV were retrospectively analyzed by matched pairs. Results: No differences were detected between patients treated with PAM or NER at the start of therapy: mean age 4.4 years (p = 0.730), mean height 86.8 cm/85.3 cm (p = 0.854), lumbar vertebral area 208.9 mm2/206.0 mm2 (p = 0.555), and in all vertebral indices. After 1 year of treatment (mean 1.16 years; p = 0.854) both groups showed a significant increase in the vertebral area and improved vertebral indices. Again there were no differences between the groups in the vertebral area (p = 0.590). Conclusion: In this study there was no difference between patients treated with PAM or NER regarding vertebral morphometry during the first year of therapy. Because of the possibility of an outpatient setting, NER is convenient for these children.

Keywords:
Osteogenesis imperfecta, Bisphosphonates, Vertebral morphometry, Neridronate, Pamidronate
1.
Rauch F, Glorieux FH: Osteogenesis imperfecta. Lancet 2004;363:1377–1385.
2.
Sillence DO, Senn A, Danks DM: Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979 1979;16:101–116.
3.
Glorieux FH, Rauch F, Plotkin H, et al: Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000;15:1650–1658.
4.
Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R: Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002;17:30–38.
5.
Labuda M, Morissette J, Ward LM, et al: Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002;31:19–25.
6.
Rauch F, Lalic L, Roughley P, Glorieux FH: Genotype-phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I. Eur J Hum Genet 2010;18:642–647.
7.
Semler O, Cheung MS, Glorieux FH, Rauch F: Wormian bones in osteogenesis imperfecta: correlation to clinical findings and genotype. Am J Med Genet A 2010;152A:1681–1687.
8.
Zeitlin L, Fassier F, Glorieux FH: Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 2003;12:77–87.
9.
Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947–952.
10.
Sumnik Z, Land C, Rieger-Wettengl G, Korber F, Stabrey A, Schoenau E: Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res 2004;61:137–142.
11.
Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH: Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 2006;148:456–460.
12.
Astrom E, Soderhall S: Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998;87:64–68.
13.
Castillo H, Samson-Fang L: Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 2009;51:17–29.
14.
Choi JH, Shin YL, Yoo HW: Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. J Korean Med Sci 2007;22:209–212.
15.
Senthilnathan S, Walker E, Bishop NJ: Two doses of pamidronate in infants with osteogenesis imperfecta. Arch Dis Child 2008;93:398–400.
16.
Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N: Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab 2010;28:451–455.
17.
Vuorimies I, Toiviainen-Salo S, Hero M, Makitie O: Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr 2011;75:346–353.
18.
Rauch F, Munns CF, Land C, Cheung M, Glorieux FH: Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 2009;24:1282–1289.
19.
Akcay T, Turan S, Guran T, Bereket A: Alendronate treatment in children with osteogenesis imperfecta. Indian Pediatr 2008;45:105–109.
20.
Gatti D, Antoniazzi F, Prizzi R, et al: Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005;20:758–763.
21.
Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tato L: Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 2006;149:174–179.
22.
Adami S, Gatti D, Colapietro F, et al: Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003;18:126–130.
23.
Phillipi CA, Remmington T, Steiner RD: Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008;Oct 8(4):CD005088.
24.
Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH: Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006;39:901–906.
25.
Beccard R, Fricke O, Land C, et al: Vertebral deformities in osteogenesis imperfecta. Effects of intravenous neridronate therapy in children and adolescents. Monatsschr Kinderheilkd 2009;12:1237–1241.
26.
Gatti D, Viapiana O, Idolazzi L, Fracassi E, Adami S: Neridronic acid for the treatment of bone metabolic diseases. Expert Opin Drug Metab Toxicol 2009;5:1305–1311.
27.
Rauch F, Glorieux FH: Osteogenesis imperfecta, current and future medical treatment. Am J Med Genet C Semin Med Genet 2005;139C:31–37.
28.
Rauch F, Cornibert S, Cheung M, Glorieux FH: Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 2007;40:821–827.
29.
Pazianas M, Cooper C, Ebetino FH, Russell RG: Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010;6:325–343.
30.
Khosla S, Burr D, Cauley J, et al: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479–1491.
31.
Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F: Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 2008;153:719–720.
32.
Smith-Bindman R, Cummings SR, Steiger P, Genant HK: A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res 1991;6:25–34.
33.
Koerber F, Semler O, Demant AW, Koerber S, Schonau E, Lackner KJ: Standardized x-ray reports of the spine in osteogenesis imperfecta (in German). Rofo 2011;183:462–469.
34.
Maasalu K, Haviko T, Martson A: Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr 2003;92:452–455.
35.
Sakkers R, Kok D, Engelbert R, et al: Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a two-year randomised placebo-controlled study. Lancet 2004;363:1427–1431.
36.
Shapiro JR, Sponsellor PD: Osteogenesis imperfecta: questions and answers. Curr Opin Pediatr 2009;21:709–716.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.